Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04360174 | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension | PHASE1 | COMPLETED | 19 | — | — | Apr 25, 2018 | May 24, 2021 | Oct 1, 2024 | 5 | United States |
All adverse events will be captured throughout the study
IOP measurements at 8 am
| Arm | Type | Description |
|---|---|---|
| OTX-TIC-Cohort 1 | EXPERIMENTAL | 15 µg (formulation1) implant |
| OTX-TIC-Cohort 2 | EXPERIMENTAL | 26 µg (formulation1) implant |
| OTX-TIC-Cohort 3 | EXPERIMENTAL | 15 µg (formulation 2) implant |
| OTX-TIC-Cohort 4 | EXPERIMENTAL | 5 µg (formulation 3) implant |
| Name | Type | Description |
|---|---|---|
| OTX-TIC | DRUG | OTX-TIC implant is injection in the anterior chamber of the eye |
Inclusion Criteria: * Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma * Have IOP that is currently controlled as assessed by the Investigator * Have open, normal appearing anterior chamber angles as determined by gonioscopy Exclusion Criteria: * Have closed angle...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Bimatoprost, AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01% |
| Glaukos Corp | GKOS | 1 | — | Travoprost |